Kirkland & Ellis advised Advent International on the debt financing for its acquisition of the leading Indian listed pharma company, Suven Pharmaceuticals Limited (Suven). The acquisition, which involved an open-offer process, relied on an innovative financing structure which included an upsize of the original commitments following completion. Advent International will also explore a potential merger of Suven with its existing Indian portfolio company, Cohance Lifesciences, to establish a combined company that specialises in active pharmaceutical ingredients as well as contract development and manufacturing businesses. Read Advent International’s press release The Kirkland team was led by debt finance partner Manas Chandrashekar, with support from debt finance partner John Curran and associate Daniel Sharif.